Zoledronate Every 5 or 10 Years Reduces Fracture Risk in Women 50-60
Overview
In a 10-year randomized trial of 1054 postmenopausal women aged 50 to 60, zoledronate administered once or every 5 years significantly reduced fracture risk, particularly during years 5 to 10. The fracture risk reduction was consistent across baseline characteristics and independent of changes in bone mineral density (BMD).
Background
Fracture prevention strategies typically focus on older individuals or those with low BMD or prior fractures. Zoledronate, a bisphosphonate, has been shown to reduce fracture risk and prevent BMD loss. This study evaluated the long-term efficacy of zoledronate administered either once or every 5 years in relatively low-risk postmenopausal women aged 50 to 60 years, assessing fracture outcomes and BMD changes over a decade.
Data Highlights
Outcome
Years 0-5
Years 5-10
Morphometric Vertebral Fractures (zol-zol)
No significant reduction
58% reduction (95% CI, 21%-77%)
Morphometric Vertebral Fractures (zol-placebo)
No significant reduction
57% reduction (95% CI, 21%-77%)
Any Fracture
Similar temporal pattern to vertebral fractures
Similar temporal pattern to vertebral fractures
Major Osteoporotic Fracture
Similar temporal pattern to vertebral fractures
Similar temporal pattern to vertebral fractures
Key Findings
Zoledronate given once at baseline or every 5 years reduces fracture risk over 10 years in women aged 50-60.
Fracture risk reduction is more pronounced during years 5 to 10 than during years 0 to 5.
There were no significant interactions between treatment effect and baseline variables such as age, BMI, BMD, falls, fracture history, or estimated fracture risk.
Fracture risk reductions were independent of changes in bone mineral density over time.
Routine BMD monitoring may not be necessary for low-risk women receiving infrequent zoledronate for long-term fracture prevention.
Clinical Implications
Zoledronate administered infrequently (once or every 5 years) is effective for long-term fracture prevention in postmenopausal women aged 50 to 60 with low to moderate fracture risk. Clinicians may consider less frequent dosing schedules without routine BMD monitoring in this population, simplifying management and potentially improving adherence.
Conclusion
Infrequent zoledronate dosing provides sustained fracture risk reduction over 10 years in relatively low-risk postmenopausal women, with benefits emerging primarily after 5 years and consistent across patient subgroups. This supports its use as a long-term preventive strategy without the need for frequent BMD assessments.
References
Original Study Authors 2024 -- Efficacy of Zoledronate Administered Every 5 or 10 Years for Fracture Prevention in Women Aged 50 to 60
by Mark J Bolland, Zaynah Nisa, Anna Mellar, Chiara Gasteiger, Veronica Pinel, Borislav Mihov, Sonja Bastin, Andrew Grey, Ian R Reid, Greg Gamble, Anne Horne
